Monday, 28 May 2018

Ophthalmology Surgical Devices Market to Reach Value of Around US$ 11.0 Billion by 2025

The global ophthalmology surgical devices market is forecasted to witness a steady growth in coming years, according to Transparency Market Research (TMR). The players in the market are expected to focus on new product launches and fortifying their geographical presence and distribution channels. Key vendors in the global ophthalmology surgical devices market are Bausch & Lomb, Inc., HOYA Corporation, Johnson & Johnson Vision Care, Inc., STAAR Surgical Company, Carl Zeiss Meditec AG, IRIDEX Corporation, and Alcon.
According to TMR’s report, the global ophthalmology surgical devices market was valued at around US$ 7.0 bn in 2016 and is expected to exhibit a steady CAGR of 4.0% from 2017 to 2025, to reach value of around US$ 11.0 bn by 2025.
Among end-users, hospitals was the largest segment in 2016 and is anticipated to marginally gain market share by 2025. This is attributable to presence of the large number of hospitals, use of technologically advanced safety products, and favorable health care insurance coverage.
Geographically, North America held a major share of the global ophthalmology surgical devices market, in terms of revenue, in 2016. The trend is projected to continue from 2017 to 2025, primarily due to large pool of patients with eye disorders and the larger number of patients undergoing eye surgeries in North America than other regions.
High Incidence of Eye Related Disorders to Offer Market Opportunity
According to a report published by the World Health Organization (WHO) in 2010, cataract was responsible for causing blindness in 20 million people across the globe, which represented around 51% of the world blindness. Glaucoma was estimated to cause blindness in 4.5 million people, which accounted for around 12% of the global blindness. In addition, AMD was the third leading cause of blindness with worldwide prevalence rate of 8.7%. The growing burden of these eye conditions coupled with rising elderly population is expected to increase the need for corrective surgeries in the near future, subsequently stimulating the need for devices and systems used in these surgeries.
The continuing worldwide demographic trend of people developing myopia is expected to augment the demand for refractive surgeries required to treat the disorder in the next few years. The rate of prevalence of myopia is as high as 70% or more in countries in East Asia. Companies in the ophthalmology surgical devices market are increasingly collaborating with one another as well as with research institutes in order to develop new technologies to address the current unmet needs for eye care.
Technical Advances in Eye Surgeries to Boost Growth
Increasing demand for efficient treatment methodologies, rapid technological advancements and rising incidence rate of ocular disorders such as corneal abrasion, cataract, dry eyes are some major drivers of the ophthalmology diagnostics and surgical devices market. Enhanced cataract surgery techniques such as implantable intraocular lenses and the introduction of retinal implants are also expected to enhance market growth during the forecast period. Moreover, introduction of new products in line with the changing healthcare dynamics such as drug eluting contact lenses and handheld devices enabled with improved technology for early detection of macular degeneration and glaucoma are anticipated to improve usage rates.
Although these factors encourage the growth of the market, a dearth of skilled professionals with expertise in ophthalmic surgery, low awareness related to the ocular diseases, and lack of healthcare infrastructure mainly in developing countries can restrain the growth of global ophthalmic surgery devices market.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Veterinary Molecular Diagnostics Market to Reach a Value of US$ 792.5 Million by 2025

According to a new report published by Transparency Market Research (TMR) titled “Veterinary Molecular Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”, the global veterinary molecular diagnostics market was valued at US$ 377.2 Mn in 2016 and is projected to expand at a CAGR of 8.6% from 2017 to 2025 to reach value of US$ 792.5 Mn by 2025. This report offers a thorough understanding of the global veterinary molecular diagnostics market including key trends, drivers, restraints, and opportunities. Rising awareness about molecular diagnostics among veterinarians and general public in both developed and developing countries is expected to drive the global veterinary molecular diagnostics market in the near future. High test sensitivity and specificity and development of new products against new diseases in animals are also driving the global veterinary molecular diagnostics market. The Asia Pacific region is witnessing gradual adoption of new technologies in veterinary molecular diagnostics, increasing animal health care expenditure, and changing dynamics of the in vitro diagnostics industry. Due to this, the veterinary molecular diagnostics market in Asia Pacific is anticipated to expand at a CAGR of 9.2% from 2017 to 2025.
The global veterinary molecular diagnostics market has been witnessing a significant shift from manual systems toward automated systems. Incidence of new diseases such as helminth parasitic diseases and protozoal parasitic diseases is rising. Development of better methods such as molecular diagnostics to detect and fight these diseases promptly is expected to drive the global veterinary molecular diagnostics market in the next few years. Factors indicating the growing importance of livestock diagnostics, medicines, and vaccines such as surging demand for improved nutrition (particularly, animal protein), limited natural resources, and widened focus on food safety are anticipated to boost the veterinary molecular diagnostics market during the forecast period.
Technological Advancements to drive Global Market
Veterinary molecular diagnostics offers several advantages over the conventional diagnostic techniques such as rapid turnaround time (2.5–3 hours), high test sensitivity and specificity, and better differentiation between avirulant and birulent strains. These added advantages are anticipated to drive the global veterinary molecular diagnostics market during the forecast period. Technological advancements in devices and reagents available for veterinary molecular diagnostics have enabled veterinarians to provide proper emergency assistance to patients. Improvement in the health care infrastructure, government campaigns, and increase in per capita income have raised awareness regarding the importance of preventive care and sophisticated diagnostic tools among veterinarians and general public. Pet owners are becoming more conscious about proper and timely diagnosis of disease suffered by their pets. This rise in awareness among the people in both developed and developing countries is expected to drive the global veterinary molecular diagnostics market in the next few years. Sophisticated molecular diagnostic instruments and assays are well-recognized and validated for proper testing. However, high costs associated with these systems and assays presents a significant challenge for the market.
Kits & Reagents Segment dominates the Market, followed by Instruments & Software Segment
The global veterinary molecular diagnostics market has been segmented based on product, technology, animal type, disease indication, end-user, and geography. Based on product, the global veterinary molecular diagnostics market has been segmented into instruments & software, kits & reagents, and services. The kits & reagents segment is expected to dominate the global veterinary molecular diagnostics market during the forecast period. This is attributable to the rising number of customized kits and reagents used in disease detection and health surveillance processes. Growing inclination toward preventive animal care and diagnosis is leading to high-volume processing, which augments the demand for high-throughput instruments and software.
Polymerase Chain Reaction (PCR) to be the Most Promising Technology
Based on technology, the market has been segmented into polymerase chain reaction (PCR), microarrays, and DNA sequencing. The polymerase chain reaction (PCR) segment is anticipated to remain highly lucrative during the forecast period, owing to several advantages over the conventional detection methods; for example, quick and accurate results. In terms of animal type, the market has been segregated into companion animals and livestock animals. Based on disease indication, the market has been segmented into vector-borne diseases, respiratory pathogens detection, diarrhea pathogens detection, and others. Based on end-user, the market has been segmented into hospitals/clinics and reference laboratories.
Asia Pacific to offer Lucrative Growth Opportunities
Geographically, the global veterinary molecular diagnostics market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to be the largest market for veterinary molecular diagnostics between 2017 and 2025. Growth of the market in the region can be attributed to increase in government and private funding and large volume of tests performed in the region. The Asia Pacific region is witnessing gradual adoption of new veterinary molecular diagnostics technologies, increase in health care expenditure, and change in dynamics of the in vitro diagnostics industry. High adoption of veterinary diagnostics drugs, vaccines, and medicated feed additives for the well-being of rapidly increasing population of livestock animals in the region makes Asia Pacific one of the most lucrative markets for veterinary molecular diagnostics.
Key Players such as IDEXX Laboratories, Inc. and VCA, Inc. likely to continue to lead Global Veterinary Molecular Diagnostics Market
Major companies competing in the global veterinary molecular diagnostics market and profiled in the report are IDEXX Laboratories, Inc., VCA, Inc., Thermo Fisher Scientific, Inc., Novacyt Group, QIAGEN N.V., Biomedica Medizinprodukte GmbH & Co KG, HealthGene Corporation, and Bioneer. IDEXX Laboratories dominates the market due to high market penetration of its flagship products in the global veterinary molecular diagnostics market.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Parkinson’s Disease Therapeutics Market to Witness a CAGR of More than 10.9% from 2017 to 2025

The global Parkinson’s disease therapeutics market was valued at US$ 2.18 Bn in 2016 and is projected to register a cumulative annual growth rate (CAGR) of more than 10.9% from 2017 to 2025, according to a new report titled “Parkinson’s Disease Threapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025” published by Transparency Market Research (TMR) (. The report states that high prevalence of Parkinson’s disease, rise in geriatric population across the globe, increase in funding for clinical research and grants, etc. are expected to spur the growth of the Parkinson’s disease therapeutic drugs during the forecast period, i.e. 2017 to 2025. North America and Europe are projected to dominate the global Parkinson’s disease therapeutics market in the near future, primarily due to the large base of aging population, high clinical R&D budget to address the unmet needs of Parkinson’s disease, and increase in awareness regarding the disease in these regions. Europe is estimated to dominate the global Parkinson’s disease therapeutics market by the end of 2025, which can be ascribed to the high prevalence and rise in incidence rate of Parkinson’s disease in the developed countries in the region such as Germany, France, the U.K., and Italy, promising product pipeline, and various initiatives undertaken by the government and non-profit organizations to promote awareness regarding the disease. The Parkinson’s disease therapeutics market in Europe is expected to witness the highest CAGR of more than 11.0% from 2017-2025.
High prevalence and rise in incidence rate of Parkinson’s disease to fuel the global market
Parkinson’s disease is a highly prevalent age-related neurodegenerative disorder, affecting millions of people worldwide and causing severe impact on their physical, psychological, as well as emotional health. The exact cause of Parkinson’s disease is not known. It is largely prevalent among the geriatric population. Classifying by gender, men are one-and-half times more affected by the disease than women. According to the Parkinson’s Foundation based in the U.S., it is estimated that worldwide around 7 to 10 million people are affected by Parkinson’s disease and around 1 million Americans are living with it. However, the exact number of patients suffering from Parkinson’s disease is known due to incompleteness and inconsistency in the prevalent studies and underdiagnosed cases. According to the Global Burden of Disease Study, it is estimated that around 13 million people will be affected by Parkinson’s disease worldwide by the year 2040. China has the world’s largest population affected with Parkinson’s disease, which is an estimated 2.5 million people, and the number is likely to become double by the end of 2030, accounting for half of the world’s population suffering from the disease. The rapidly growing geriatric population, coupled with high prevalence and increasing incidence rate of Parkinson’s disease in the developed countries, is projected to a key driving factor of the Parkinson’s disease therapeutics market during the forecast period.
Levodopa combination drugs to be an attractive product segment
The report offers detailed segmentation of the global Parkinson’s disease therapeutics market based on drug class, route of administration, and distribution channel. Among drug classes, the levodopa combination drugs segment is poised to account for the leading share of the global market during the forecast period from 2017 to 2025. Levodopa combination therapy is considered a highly-effective treatment for the motor symptoms associated with Parkinson’s disease and is commonly recommended by physicians across the globe. Carbidopa and levodopa combination therapy is commonly used for management of motor fluctuations in Parkinson’s disease. The recent approval by the United States FDA and launch of Duopa in 2015 by AbbVie Inc. had significantly promoted levodopa combination drugs in 2016. Also, the anticipated launch of pipeline study of CVT-301 by Acorda Therapeutics, Inc. and ND0612 from Mitsubishi Tanabe by the end of 2019 is estimated to propel the segment’s growth during the forecast period
Oral route of administration, followed by intestinal infusion segment, dominates the market
In terms of route of administration, the oral route is projected to dominate the global Parkinson’s disease therapeutics market during the forecast period and is estimated to expand at a CAGR of more than 7.5% from 2017-2025. More than 70% of the drugs available for treatment of Parkinson’s disease are in the tablet and capsule form. Some of the drugs are orally disintegrated. However, the estimated launch of sublingual film by SUNOVION and inhaled formulation by Acorda Therapeutics, Inc. during the forecast period is likely to gain market exceeding 15% by the end of 2025. Also, rise in adoption and demand for subcutaneous injections and promising pipeline products with subcutaneous route of administration for home management of Parkinson’s disease are estimated to limit the growth of the oral route of administration segment by the end of 2025.
Retail pharmacy, followed by hospital pharmacy segment, dominates the market
Among distribution channels, the retail pharmacy segment is projected to hold the dominant share of the global Parkinson’s disease therapeutics market during the forecast period and is likely to expand at CAGR of more than 11% from 2017 to 2025. Easy availability of Parkinson’s therapeutic drugs at retail pharmacies, low price of the drugs, and expansion of leading retail pharmaceutical chains across the globe are driving the growth of the segment. The hospital pharmacy segment is the second leading shareholder of the global Parkinson’s disease therapeutics market. However, the segment is likely to lose its market share by the end of 2025. Intestinal infusion drugs and subcutaneously administered drugs, and certain patented drugs, to an extent, have contributed to the key market share of the hospital pharmacy segment in 2016. The online pharmacy segment is poised to grow at as significant CAGR of more than 12% during the forecast period.
Huge incremental opportunity in Europe
In terms of value, Europe dominated the global Parkinson’s disease therapeutics market in 2016. The region is estimated to gain market share by the end of 2025. The dominance of Europe can be primarily attributed to the high prevalence of Parkinson’s disease in the region, availability of and high adoption of levodopa combination drugs, and high clinical R&D budget to address the unmet needs in Parkinson’s disease. According to the European Parkinson’s Disease Association, around 1.2 million people in European Union are affected with Parkinson’s disease. In Germany, around 260,000 people; in Italy, 150,000 people; and in the U.K., around 120,000 people are affected by the disease. The highest incidence rate of Parkinson’s disease is observed in France with around 36-49 cases per 100,000 people. The Parkinson’s disease therapeutics market in Europe is estimated to grow at the highest CAGR of more than 11% during the forecast period. North America is the second leading market for Parkinson’s disease therapeutics. Rapid growth in the aging population of the U.S., rise in awareness regarding Parkinson’s disease, and new product approvals and launches in the region have contributed to the dominant share of the region. Moreover, high clinical R&D budget by the governments, private players, and non-profit organizations are estimated to fuel the expansion of the Parkinson’s disease therapeutics market in North America during the forecast period. The Parkinson’s disease therapeutics market in Asia Pacific is poised to grow at a moderate rate during the forecast period.
Key trend of new product development and launch in the international market is observed among leading players
The report also provides profiles of the leading players operating in the global Parkinson’s disease therapeutics market. AbbVie Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., and UCB Inc. are some of the prominent players in the market having proprietary products and technologies. Most of them are focused on new product development, approvals, and commercialization of novel drugs to gain the first-mover’s advantage and address the unmet needs in the Parkinson’s disease therapeutics market. For instance, In January 2015, AbbVie’s flagship product, DUOPA (Combination Drug of carbidopa and levodopa), received the approval of the United States FDA for the treatment of advanced Parkinson’s disease. Duopa is administered through a unique technology directly into the intestine of the patient through the stoma. It is the first and only kind of product administered through intestinal infusion. In 2016, the ACADIA Pharmaceuticals Inc. launched its antipsychotic drug, Nuplazid, in the U.S. Nuplazid is the first and only drug approved by the United States FDA for the management of hallucination and delusion associated with Parkinson’s disease. Other prominent players operating in the global Parkinson’s disease therapeutics market include STADA Arzneimittel AG, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc., and Impax Laboratories Inc.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Animal Blood Plasma Products and Derivatives Market to Reach a Value of US$ 1.92 Billion by 2024

The global animal blood plasma products and derivatives market features a fairly fragmented landscape with the presence of a large number of players. However, intense competition exists between a few large players. The combined share of leading companies such as Proliant, Thermo Fisher Scientific, and Sigma-Aldrich collectively, exceeded 76.0% of the market in 2016, with Proliant holding the dominant share, notes Transparency Market Research (TMR). Several vendors are actively consolidating their distribution networks across various regions by forming strategic partnerships with a number of indigenous distributors, raw materials suppliers, and manufacturers. Numerous companies based in developed nations are expected to expand their presence in emerging markets by opting for mergers, acquisitions, and partnerships, in order to strengthen their presence, observes TMR.
The global market for animal blood plasma products and derivatives was valued at US$1.04 bn in 2015. Rising at a CAGR of 7.10% during 2016–2024, the opportunities in the market is anticipated to reach US$1.92 bn by the end of 2024.
Numerous Applications of Blood Plasma in Food Industry Reflect Positively on Market
Geographically, North America occupied the major market share in 2015 and is expected to retain its lead throughout the forecast period. The growth of this regional market is driven by the presence of several prominent players who are constantly offering innovative products for varied cell culture applications by actively focusing on a diversified portfolio of cell lines.
The major applications areas of animal blood plasma products and derivatives are cell culture media, nutrition supplements, sports nutrition, the pharmaceutical industry, the food industry, the cosmetic industry, the pet food industry, and the diagnostics industry. Of these, the food industry is projected to grow at a substantial pace over the forecast period. The growth of this segment is attributed to the wide applications of plasma in making food products in various developed markets.
Constant Advancements in Blood Collection and Processing Techniques Boost Market
The developments in the global animal blood plasma products and derivatives market is primarily driven by applications of animal blood plasma in the food industry, especially for making pet food. The utilization of blood plasma and derivatives in the food industry is largely motivated by scores of nutritional benefits, along with economic and environmental ones. The burgeoning demand for premium quality and healthy solutions of blood plasma products in making a variety of wet pet foods and pet snacks is a key factor boosting the market. In addition, the growing application of blood plasma and derivatives to increasingly substitute plant-extracted proteins for making pet food bodes well for the market. Furthermore, constant improvements in supply chain and distribution networks by various players is expected to positively impact the animal blood plasma products and derivatives market.
Recent advances in blood collection and processing techniques have catalyzed the market. The availability of modern blood processing technologies in North America is expected to fuel the market growth in the coming years. For instance, substantial efforts have been focused on augmenting the utility of the cellular fraction in food proteins, which is expected to propel the market over the forecast period. The increasing import of animals to advanced regions from countries such as Australia and New Zealand is expected to accelerate blood collection processes, thereby accentuating the market.
However, marked price volatility in animal blood plasma products, coupled with rising prevalence of diseases among animals, is a key factor hindering the market growth to an extent. Nevertheless, recent advancements in techniques for processing blood plasma and derivatives are expected to open up exciting opportunities for market players in major regions. Furthermore, the growing significance of cell culture media in conventional research and for the development of vital biomolecules and therapeutics is expected to open up lucrative growth avenues for players to capitalize on in the forthcoming years.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Medical Nonwoven Disposables Market will be Worth US$ 18.4 Billion by the End of 2024

The global medical nonwoven disposable market is fragmented in nature. The top three players in the market, namely Kimberly-Clark Corporation, Paul Hartmann AG, and Svenska Cellulosa, together held just 39.3% share in it in 2015. In order to stay ahead of competition in such a fragmented market, keen companies are resorting to diversification of their product portfolio and tapping into high growth regions through strategic mergers and acquisitions.
A report by Transparency Market Research studies the global market for medical nonwoven disposable and estimates that it would rise at a lackluster 4.0% CAGR during the period from 2016 to 2024. It projects the market, which was valued at US$12.9 bn in 2015, to attain a value of US$18.4 bn by the end of 2024.
Some of the key products available in the market are wound dressings, surgical products, and incontinence products. Of them, surgical products lead the market with maximum share. In surgical products again, the segment of drapes are most widely used. Surgical caps, gowns, and masks are also predicted to see swift uptake in the years ahead. Overall, the surgical segment is expected to account for a share of 52.0% by 2024-end.
Geographically, Latin America, North America, Europe, Asia Pacific, and the Middle East and Africa are the key regions studied in the report. North America currently holds a leading position in the market on the back of favorable reimbursement policies that encourage more people to opt for quality healthcare. Other than that a superior healthcare infrastructure coupled with continued innovations by savvy players domiciled in the region is also serving to stoke the market in the region.
Rising Geriatric Population Driving Demand
Mainly serving to catalyze growth in the global market for medical nonwoven disposable are the growing pool of elderly who are highly susceptible to various infections and illnesses. The market is also expected to benefit from the rising occurrence of epidemics such as H1N1 virus, Ebola, Chikungunya, and SARS. These epidemics are at the forefront of driving demand for medical nonwoven disposables, which prevent the infection from spreading by offering a protective covering for doctors and nurses trying to treat patients.
Another major growth driver in the global market for non-woven disposables is soaring demand for superior technology in manufacturing better quality products. For example, patients and doctors are increasingly going for products with anti-microbial properties and high absorbency in order to drastically reduce the chances of cross-contamination.
Government Initiatives to Prevent Infections Spurs Growth in Market
Apart from that, growing number of government initiatives and schemes that are meant to thwart various types of infections and simultaneously improve the manufacturing capabilities, is also providing a tailwind to the global market for non-woven disposables. “The market is being stoked by the rise in awareness on nosocomial infections too,” explains the lead analyst of the TMR report.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Endometrial Ablation Market Value to Reach US$ 1.3 Billion by the End of 2024

The presence of a number of large endometrial ablation enterprises such as Cooper Surgical Inc., Medtronic Plc, Boston Scientific Corp., Ethicon Inc., and Hologic Corp., has rendered the vendor landscape of the global endometrial ablation market highly competitive, observes Transparency Market Research in a recent report. To supersede competitors, companies in the market are focusing on growth strategies such as introduction of technologically advanced products and expansion across new regional markets. Owing to these trends, the market has witnessed a vast rise in collaborations, mergers, and acquisitions, leading to a further intensified level of competition.
TMR estimates that the global market for endometrial ablation will exhibit a promising CAGR of 5.50% from 2016 to 2024, rising from an opportunity worth US$0.8 bn in 2015 to US$1.3 bn by 2024.
North America to Continue to Command Greater Hold on Global Market
In terms of type of devices, the segment of radiofrequency endometrial ablation devices held the dominant share in market’s overall revenue in. The segment is likely to also continue to lead over the report’s forecast period. Factors such as ease of usage, less duration required for surgery, and cost benefits will continue to bode well for the segment over the forecast period, by the end of which the segment is expected to account for a nearly 58% of the overall market. In terms of geography, the market for endometrial ablation in North America is presently the leading contributor in terms of revenue and is likely to retain the top spot throughout the report’s forecast, thanks to the developed healthcare infrastructure. The regional market is projected to hold a nearly 44% of the overall market by 2024.
Rising Rate of Incidence of Gynecological Diseases to Drive Market
The market is expected to benefit from a number of factors, which will be seen in its steady growth path over the course of the report’s forecast. The key drivers of the market will be factors such as the vast rise in the global prevalence of gynecological disorders, the easy availability of technologically advanced endometrial ablation devices, and high cost of ablation surgeries. The market will also benefit from the rising population of affluent higher middle-class people, especially across emerging economies in regions such as Asia Pacific and Latin America, and the increased expenditure of the world population on advanced healthcare treatments.
The increased rate of incidence of gynecological conditions such as polycystic ovarian disease (PCOD), abnormal vaginal bleeding, and endometrial and cervical cancers in the past few years has boosted the demand for effective treatments. These factors remain at the helm of the remarkable development achieved by the global endometrial ablation market in the past few years and will continue to lead it towards a healthy growth path in the near future.
Increased Preference to Non-invasive Treatments to Bode Well for Market
Despite having healthy growth prospects in the foreseeable future, the market faces challenges such as issues concerning commercialization in developing and under-developed economies and strict regulatory laws and policies in developed economies. Nevertheless, as the global consumer becomes more educated about the vast benefits of non-invasive treatments, in terms of faster recovery, reduced time in hospitals, and cost of the overall treatment, the market will continue to witness a healthy rise in demand. The vast pool of untapped growth opportunities in emerging economies could also act as a good opportunity for companies aspiring to strengthen their hold on the global endometrial ablation market.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Cryptococcosis Market to Expand at a CAGR of 4.8% from 2016 to 2024

The global market for cryptococcosis exhibits a highly fragmented competitive landscape due to the presence of a large number of small, medium, and large scale vendors. Although the market is currently cluttered with the presence of numerous players, the global market for cryptococcosis was characterized by the presence of only a handful of players a couple of decades back. The market players who have existed in the market for a longer period of time have established their strongholds as against other relatively new vendors. However, it is doubtful that any of the leading players have been able to make handsome profits over the course of their existence. This is because the scope for research and development while formulating lines of treatment for cryptococcosis is extremely petty.
The market vendors have been trying to emulate successful research pathways for treatment and cure of cryptococcosis but to no avail. The competition amongst the leading market players has been rising over the past years, and the entry of new players has added to the woes of the established players. It is anticipated that the market players would increase their investments in research and development to outdo the competitors. Furthermore, the large market players are expected to form strategic alliances in order to retain their supremacy in the market. Some of the key players in the global market for cryptococcosis are Bristol-Myers Squibb Company, Pfizer, Inc., and Valeant Pharmaceuticals, Inc.
The global cryptococcosis market is expected to grow at a steady CAGR of 4.80% over the period between 2016 and 2024. Moreover, the global market registered a total revenue of US$4.31 bn in 2016 and this figure is expected to elevate to US$6.2 bn by 2024-end.
Prevalence of HIV Drives Demand
Cryptococcosis is mostly diagnosed in patients who are HIV positive, and hence, the rising number of such patients has given a boost to the demand within the global market cryptococcosis. Moreover, cryptococcosis was considered to be a rare disease a decade ago, but the world has witnessed an upsurge in the number of cases of the disease in recent times. This has been a key factor that has driven demand within the global market for cryptococcosis. The healthcare industry has been increasingly concerned with regards to the treatment of the disease following which the demand for amphotericin B plus oral flucytosin (an antidote for cryptococcosis) has risen across the globe. The handsome investments made by governments and international healthcare centers for the development of better drugs has also accelerated the growth of the global market for cryptococcosis.
High Mortality Rate Associated with Cryptococcosis to Hamper Market Growth
The high mortality rate of patients diagnosed with cryptococcosis has been a major roadblock to the growth of the global market for cryptococcosis. The mortality rate of HIV positive patients who simultaneously develop cryptococcosis almost tends towards 100%. This does not allow proper research about the causes, triggers, and therapeutic actions for cryptococcosis. Furthermore, the low cost of generic drugs has disabled the large market players from reaching out to the patients or consumers.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)